RAD21 and acute myeloid leukemia: Importantly, this pattern was distinct from the outcomes of RAD21-mutant AML, which was almost identical to AML-non-MR and significantly better than STAG2-mutant AML OS (HR = 0.56, 95% CI = 0.34–0.93, median OS 48 vs. 16 months p = 0.024) (Fig. 4C, Supplementary Fig. 11A, B).